Ton Lisman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4073102/publications.pdf

Version: 2024-02-01

365 papers	15,956 citations	13099 68 h-index	24258 110 g-index
400 all docs	400 docs citations	400 times ranked	11322 citing authors

#	Article	IF	Citations
1	Antithrombotic Management in Adult Kidney Transplantation: A European Survey Study. European Surgical Research, 2023, 64, 169-176.	1.3	1
2	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. Thrombosis and Haemostasis, 2022, 122, 353-362.	3.4	7
3	Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrinâ€rich thrombus. Hepatology, 2022, 75, 898-911.	7.3	28
4	Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome. Hepatology, 2022, 75, 623-633.	7.3	25
5	Reply to: Correspondence on â€œPredicting portal thrombosis in cirrosis: A prospective study of clinical, ultrasonographic and hemostatic factorsâ€• Journal of Hepatology, 2022, 76, 227-228.	3.7	0
6	Reply. Hepatology, 2022, 75, 499-499.	7.3	0
7	Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2022, 20, 39-47.	3.8	39
8	Persistent endotheliopathy in the pathogenesis of long COVID syndrome: Comment from von Meijenfeldt et al.. Journal of Thrombosis and Haemostasis, 2022, 20, 267-269.	3.8	10
9	Long-term normothermic machine preservation of human livers: what is needed to succeed?. American Journal of Physiology - Renal Physiology, 2022, 322, G183-G200.	3.4	10
10	Reply. Hepatology, 2022, 75, 770-771.	7.3	0
11	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. Journal of Hepatology, 2022, 76, 1090-1099.	3.7	26
12	Effects of Inflammation on Hemostasis in Acutely Ill Patients with Liver Disease. Seminars in Thrombosis and Hemostasis, 2022, 48, 596-606.	2.7	7
13	EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. Journal of Hepatology, 2022, 76, 1151-1184.	3.7	112
14	Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates. Liver International, 2022, 42, 435-443.	3.9	8
15	Pathophysiology and management of bleeding and thrombosis in patients with liver disease. International Journal of Laboratory Hematology, 2022, 44, 79-88.	1.3	4
16	Acquired bleeding disorders. Haemophilia, 2022, 28, 68-76.	2.1	7
17	Haemostatic alterations and management of haemostasis in patients with cirrhosis. Journal of Hepatology, 2022, 76, 1291-1305.	3.7	33
18	Lower-leg injury and knee arthroscopy have distinct effects on coagulation. Blood Advances, 2022, 6, 5232-5243.	5.2	2

#	Article	IF	Citations
19	The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study. Journal of Thrombosis and Haemostasis, 2022, 20, 2075-2082.	3.8	16
20	Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of tissue factor and activated factor VII. Journal of Thrombosis and Haemostasis, 2022, 20, 2306-2312.	3.8	6
21	On coagulation in advanced chronic liver disease and the origin of freshwater eels. Journal of Hepatology, 2022, 77, 886-887.	3.7	1
22	The international normalized ratio â€“ Great for prediction of bleeding in patients taking vitamin K antagonists, useless for prediction of bleeding in patients with chronic liver disease. Journal of Thrombosis and Haemostasis, 2022, 20, 1565-1567.	3.8	0
23	Unravelling the Role of Neutrophil Extracellular Traps in Acute Liver Failure. Cellular and Molecular Gastroenterology and Hepatology, 2022, , .	4.5	0
24	Acquired bleeding disorders. Haemophilia, 2021, 27, 5-13.	2.1	9
25	VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure. Hepatology, 2021, 73, 1882-1891.	7.3	36
26	Global hemostatic status in patients with acuteâ€onâ€chronic liver failure and septics without underlying liver disease. Journal of Thrombosis and Haemostasis, 2021, 19, 85-95.	3.8	38
27	Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortalityâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 878-882.	2.4	157
28	Prothrombotic changes in patients with COVIDâ€19 are associated with disease severity and mortality. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 132-141.	2.3	69
29	Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 988-994.	2.4	146
30	Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease. Journal of Thrombosis and Haemostasis, 2021, 19, 664-676.	3.8	29
31	Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 73, 366-413.	7.3	295
32	Transfusion with Cryoprecipitate for Very Low Fibrinogen Levels Does Not Affect Bleeding or Survival in Critically Ill Cirrhosis Patients. Thrombosis and Haemostasis, 2021, 121, 1317-1325.	3.4	23
33	Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Advances, 2021, 5, 756-759.	5.2	84
34	Controlled DCD Liver Transplantation Is not Associated With Increased Hyper-fibrinolysis and Blood Loss After Graft Reperfusion. Transplantation, 2021, Publish Ahead of Print, .	1.0	0
35	Donor genetic variants as risk factors for thrombosis after liver transplantation: A genome-wide association study. American Journal of Transplantation, 2021, 21, 3133-3147.	4.7	4
36	COVID-19 is Associated with an Acquired Factor XIII Deficiency. Thrombosis and Haemostasis, 2021, 121, 1668-1669.	3.4	15

#	Article	IF	Citations
37	Hemostatic balance in acuteâ€onâ€chronic liver failure. Journal of Thrombosis and Haemostasis, 2021, 19, 869-870.	3.8	1
38	The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. Journal of Thrombosis and Haemostasis, 2021, 19, 1116-1122.	3.8	66
39	Fibrinolysis in Patients with Liver Disease. Seminars in Thrombosis and Hemostasis, 2021, 47, 601-609.	2.7	11
40	Major Thromboembolic Complications in Liver Transplantation: The Role of Rotational Thrombelastometry and Cryoprecipitate Transfusion. Transplantation, 2021, 105, e58-e59.	1.0	1
41	Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis. Journal of Thrombosis and Haemostasis, 2021, 19, 1472-1482.	3.8	3
42	Hemostatic and Nonhemostatic Effects of Heparan Sulfate Proteoglycans. Seminars in Thrombosis and Hemostasis, 2021, 47, 238-239.	2.7	3
43	Histological Analysis of Donor Lung Derived Thrombi. Journal of Heart and Lung Transplantation, 2021, 40, S326-S327.	0.6	0
44	Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome. Journal of Hepatology, 2021, 74, 1264-1265.	3.7	6
45	Response by Mackman et al to Letter Regarding Article, â€œPatients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortalityâ€”Brief Reportâ€. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, e381-e382.	2.4	7
46	Treatment of bleeding in patients with liver disease. Journal of Thrombosis and Haemostasis, 2021, 19, 1644-1652.	3.8	16
47	Preface: Altered Fibrinolysisâ€”Clinical Impact and Diagnostic Challenges. Seminars in Thrombosis and Hemostasis, 2021, 47, 477-479.	2.7	3
48	Sustained prothrombotic changes in convalescent patients with COVID-19. Lancet Haematology,the, 2021, 8, e475.	4.6	5
49	Safety of direct oral anticoagulants in patients with advanced liver disease. Liver International, 2021, 41, 2159-2170.	3.9	36
50	Aprotinin Inhibits Thrombin Generation by Inhibition of the Intrinsic Pathway, but is not a Direct Thrombin Inhibitor. TH Open, 2021, 05, e363-e375.	1.4	2
51	Tranexamic Acid Is Not a Universal Hemostatic Agent. HemaSphere, 2021, 5, e625.	2.7	3
52	Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. Journal of Hepatology, 2021, 75, 1367-1376.	3.7	73
53	Heparin â€“ Messias or Verschlimmbesserung?. Journal of Thrombosis and Haemostasis, 2021, 19, 2373-2382.	3.8	8
54	Fresh frozen plasma in treating acute variceal bleeding: Not effective and likely harmful. Liver International, 2021, 41, 1710-1712.	3.9	2

#	Article	IF	Citations
55	Soluble angiotensinâ€converting enzyme 2 is transiently elevated in COVIDâ€19 and correlates with specific inflammatory and endothelial markers. Journal of Medical Virology, 2021, 93, 5908-5916.	5.0	50
56	Dual Versus Single Oxygenated Hypothermic Machine Perfusion of Porcine Livers: Impact on Hepatobiliary and Endothelial Cell Injury. Transplantation Direct, 2021, 7, e741.	1.6	15
57	Therapeutic anticoagulation after liver transplantation is not useful among patients with preâ€transplant Yerdelâ€grade I/II portal vein thrombosis: A twoâ€center retrospective study. Journal of Thrombosis and Haemostasis, 2021, 19, 2760-2771.	3.8	2
58	Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure. Hepatology, 2021, 74, 937-949.	7.3	20
59	Aggravation of fibrin deposition and microthrombus formation within the graft during kidney transplantation. Scientific Reports, 2021, 11, 18937.	3.3	7
60	Elevated factor V activity and antigen levels in patients with Covidâ€19 are related to disease severity and 30â€day mortality. American Journal of Hematology, 2021, 96, E98-E100.	4.1	6
61	Oxygen Transport during Ex Situ Machine Perfusion of Donor Livers Using Red Blood Cells or Artificial Oxygen Carriers. International Journal of Molecular Sciences, 2021, 22, 235.	4.1	26
62	A high-dose 24-hour tranexamic acid infusion for the treatment of significant gastrointestinal bleeding: HALT-IT RCT. Health Technology Assessment, 2021, 25, 1-86.	2.8	4
63	Fibrinolytic Shutdown in COVID-19 Is Likely a Misnomer. Shock, 2021, 55, 844-845.	2.1	4
64	Factor VIII/protein C ratio independently predicts liver-related events but does not reflect the hypercoagulable state in patients with advanced-chronic liver disease. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
65	Clinical Cirrhosis Dilemmas: Survey of Practice from the 7th International Coagulation in Liver Disease Conference. Digestive Diseases and Sciences, 2020, 65, 1334-1339.	2.3	6
66	Von Willebrand factor delays liver repair after acetaminophen-induced acute liver injury in mice. Journal of Hepatology, 2020, 72, 146-155.	3.7	39
67	Nails in the coffin of fresh frozen plasma to prevent or treat bleeding in cirrhosis?. Journal of Hepatology, 2020, 72, 12-13.	3.7	12
68	Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acuteâ€onâ€Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival. Hepatology, 2020, 71, 1381-1390.	7.3	63
69	Evidence for a rebalanced hemostatic system in pediatric liver transplantation: A prospective cohort study. American Journal of Transplantation, 2020, 20, 1384-1392.	4.7	13
70	Reply. Liver Transplantation, 2020, 26, 604-605.	2.4	0
71	The Authorsâ€™ Reply to Letter to the Editor, Re: Biliary Bicarbonate, pH, and Glucose Are Suitable Biomarkers of Biliary Viability During Ex Situ Normothermic Machine Perfusion of Human Donor Livers. Transplantation, 2020, 104, e41-e41.	1.0	0
72	In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVIDâ€19 patients on anticoagulation. Journal of Thrombosis and Haemostasis, 2020, 18, 2646-2653.	3.8	108

#	Article	IF	Citations
73	Anticoagulant Management and Synthesis of Hemostatic Proteins during Machine Preservation of Livers for Transplantation. Seminars in Thrombosis and Hemostasis, 2020, 46, 743-750.	2.7	6
74	Linkage analysis combined with whole-exome sequencing identifies a novel prothrombin (F2) gene mutation in a Dutch Caucasian family with unexplained thrombosis. Haematologica, 2020, 105, e370-e372.	3.5	6
75	Efficacy of proâ€•and anticoagulant strategies in plasma of patients undergoing hepatobiliary surgery. Journal of Thrombosis and Haemostasis, 2020, 18, 2840-2851.	3.8	8
76	Preanalytical variables affect thrombomodulin-modified thrombin generation in healthy volunteers. Thrombosis Research, 2020, 194, 237-239.	1.7	8
77	Pulmonary Megakaryocytes in Coronavirus Disease 2019 (COVID-19): Roles in Thrombi and Fibrosis. Seminars in Thrombosis and Hemostasis, 2020, 46, 831-834.	2.7	24
78	Blood Markers of Portal Hypertension Are Associated with Blood Loss and Transfusion Requirements during Orthotopic Liver Transplantation. Seminars in Thrombosis and Hemostasis, 2020, 46, 751-756.	2.7	6
79	Metformin Preconditioning Improves Hepatobiliary Function and Reduces Injury in a Rat Model of Normothermic Machine Perfusion and Orthotopic Transplantation. Transplantation, 2020, 104, e271-e280.	1.0	12
80	The VWF/ADAMTS13 unbalance, but not global coagulation or fibrinolytic status, is associated with outcome and bleeding in patients with acute liver failure. Journal of Hepatology, 2020, 73, S24-S25.	3.7	5
81	Bleeding and Thrombosis in Patients with Liver Diseases. Seminars in Thrombosis and Hemostasis, 2020, 46, 653-655.	2.7	3
82	Differentiating biochemical from clinical heparin resistance in COVID-19. Journal of Thrombosis and Thrombolysis, 2020, 50, 1015-1016.	2.1	10
83	The Spectrum of Disease Severity in Cirrhosis and Its Implications for Hemostasis. Seminars in Thrombosis and Hemostasis, 2020, 46, 716-723.	2.7	9
84	Thrombin Generation and Cirrhosis: State of the Art and Perspectives. Seminars in Thrombosis and Hemostasis, 2020, 46, 693-703.	2.7	33
85	Global hemostatic status in patients with acute-on-chronic liver failure and patients with sepsis without underlying liver disease. Journal of Hepatology, 2020, 73, S496-S497.	3.7	0
86	A hypercoagulable state does not play a major role in the development of portal vein thrombosis in patients with cirrhosis. Journal of Hepatology, 2020, 73, S711-S712.	3.7	2
87	Author response to Letter to the Editor: â€˜ABO, von Willebrand factor/Factor VIII and portal vein thrombosis in decompensated cirrhosis: Too late to unmask the culprit?â€™. Liver International, 2020, 40, 1790-1791.	3.9	3
88	Anticoagulant activity of edoxaban in patients with cirrhosis. Blood, 2020, 136, 1561-1564.	1.4	14
89	Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet, The, 2020, 395, 1927-1936.	13.7	224
90	Extended hypothermic oxygenated machine perfusion enables ex situ preservation of porcine livers for up to 24 hours. JHEP Reports, 2020, 2, 100092.	4.9	34

#	Article	IF	Citations
91	Interpreting Hemostatic Profiles Assessed With Viscoelastic Tests in Patients With Cirrhosis. Journal of Clinical Gastroenterology, 2020, 54, 389-391.	2.2	27
92	Donor tobacco smoking is associated with postoperative thrombosis after primary liver transplantation. Journal of Thrombosis and Haemostasis, 2020, 18, 2590-2600.	3.8	4
93	In Vitro Evaluation of Pro- and Anticoagulant Drugs in Children with End-Stage Liver Disease Undergoing Liver Transplantation. Thrombosis and Haemostasis, 2020, 120, 1240-1247.	3.4	5
94	Hemostatic Changes of Acute Kidney Injury in Patients With Cirrhosis: What Do They Mean?. Hepatology, 2020, 72, 1163-1165.	7.3	1
95	Nanomedicine in Thrombosis and Hemostasis: The Future of Nanotechnology in Thrombosis and Hemostasis Research and Clinical Applications. Seminars in Thrombosis and Hemostasis, 2020, 46, 521-523.	2.7	3
96	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. Liver International, 2020, 40, 1415-1426.	3.9	21
97	Routine Postoperative Antithrombotic Therapy in Pediatric Liver Transplantation: Impact on Bleeding and Thrombotic Complications. Thrombosis and Haemostasis, 2020, 120, 627-637.	3.4	7
98	Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay. Journal of Thrombosis and Haemostasis, 2020, 18, 834-843.	3.8	22
99	INCREASED DEVELOPMENT OF MICROTHROMBI AND FIBRIN DEPOSITIONS IN DECEASED DONOR KIDNEY TRANSPLANTATION. Transplantation, 2020, 104, S380-S380.	1.0	0
100	Plasma From Patients Undergoing Liver Transplantation Is Resistant to Anticoagulant Activity of Soluble Thrombomodulin. Liver Transplantation, 2019, 25, 252-259.	2.4	2
101	Perioperative hemostatic management in the cirrhotic patient: a position paper on behalf of the Liver Intensive Care Group of Europe (LICAGE). Minerva Anestesiologica, 2019, 85, 782-798.	1.0	46
102	Plasma levels of circulating DNA are associated with outcome, but not with activation of coagulation in decompensated cirrhosis and ACLF. JHEP Reports, 2019, 1, 179-187.	4.9	21
103	SAT-017-Anticoagulant effect of edoxaban in patients with cirrhosis: The POET study. Journal of Hepatology, 2019, 70, e632-e633.	3.7	1
104	Transplantation of high-risk donor livers after resuscitation and viability assessment using a combined protocol of oxygenated hypothermic, rewarming and normothermic machine perfusion: study protocol for a prospective, single-arm study (DHOPE-COR-NMP trial). BMJ Open, 2019, 9, e028596.	1.9	26
105	Intrahepatic fibrin(ogen) deposition drives liver regeneration after partial hepatectomy in mice and humans. Blood, 2019, 133, 1245-1256.	1.4	46
106	Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis. Thrombosis and Haemostasis, 2019, 119, 246-253.	3.4	52
107	Decreased Fibrinolytic Capacity in Cirrhosis and Liver Transplantation Outcomes. Liver Transplantation, 2019, 25, 359-361.	2.4	6
108	SAT-077-Intraperitoneal activation of blood coagulation via tissue factor-exposing extracellular vesicles in patients with advanced chronic liver disease. Journal of Hepatology, 2019, 70, e661.	3.7	0

#	Article	IF	Citations
109	Biliary Bicarbonate, pH, and Glucose Are Suitable Biomarkers of Biliary Viability During Ex Situ Normothermic Machine Perfusion of Human Donor Livers. Transplantation, 2019, 103, 1405-1413.	1.0	133
110	Evaluation of hemostasis in patients with end-stage renal disease. PLoS ONE, 2019, 14, e0212237.	2.5	43
111	Transplantation of High-risk Donor Livers After Ex Situ Resuscitation and Assessment Using Combined Hypo- and Normothermic Machine Perfusion. Annals of Surgery, 2019, 270, 906-914.	4.2	161
112	Crosslinked clots formed independently of factorÂXIIIand without fibrinogenâ€toâ€fibrin conversion â€“ is this a liverâ€specific phenomenon?. Journal of Thrombosis and Haemostasis, 2019, 17, 110-112.	3.8	1
113	Chronic liver injury drives nonâ€traditional intrahepatic fibrin(ogen) crosslinking via tissue transglutaminase. Journal of Thrombosis and Haemostasis, 2019, 17, 113-125.	3.8	21
114	Reply. Liver Transplantation, 2019, 25, 182-183.	2.4	0
115	Perioperative antithrombotic therapy does not increase the incidence of early postoperative thromboembolic complications and bleeding in kidney transplantation â€“ a retrospective study. Transplant International, 2019, 32, 418-430.	1.6	10
116	Peribiliary Glands Are Key in Regeneration of the Human Biliary Epithelium After Severe Bile Duct Injury. Hepatology, 2019, 69, 1719-1734.	7.3	44
117	Understanding and Managing the Coagulopathy of Liver Disease. , 2019, , 734-746.		0
118	The impact of ABO blood type on VWF and factor VIII levels and the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
119	Intraperitoneal activation of the coagulation system via tissue factor-exposing extracellular vesicles and enhanced fibrinolysis in patients with advanced chronic liver disease and ascites. , 2019, 57, .		0
120	Removal of destructive brain-borne microdust. Blood, 2018, 131, 477-478.	1.4	0
121	Extrahemostatic Functions of Platelets and Coagulation Factors. Seminars in Thrombosis and Hemostasis, 2018, 44, 089-090.	2.7	11
122	Mechanisms of enhanced thrombinâ€generating capacity in patients with cirrhosis. Journal of Thrombosis and Haemostasis, 2018, 16, 1128-1131.	3.8	24
123	Fibrin fuels fatty liver disease. Journal of Thrombosis and Haemostasis, 2018, 16, 3-5.	3.8	9
124	Normothermic machine perfusion of donor livers without the need for human blood products. Liver Transplantation, 2018, 24, 528-538.	2.4	81
125	Systematic comparison of routine laboratory measurements with in-hospital mortality: ICU-Labome, a large cohort study of critically ill patients. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1140-1151.	2.3	5
126	Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study. Thrombosis and Haemostasis, 2018, 118, 152-160.	3.4	15

#	Article	IF	Citations
127	Plateletâ€leucocyte aggregation is augmented in cirrhosis and further increased by platelet transfusion. Alimentary Pharmacology and Therapeutics, 2018, 47, 1375-1386.	3.7	17
128	Comment to â€œAntithrombin III administration for portal vein thrombosis in patients with liver disease: A randomized doubleâ€blind controlled trialâ€. Hepatology Research, 2018, 48, E379-E380.	3.4	1
129	Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. Journal of Critical Care, 2018, 43, 54-60.	2.2	87
130	Platelets as Modulators of Liver Diseases. Seminars in Thrombosis and Hemostasis, 2018, 44, 114-125.	2.7	46
131	Plateletâ€“neutrophil interactions as drivers of inflammatory and thrombotic disease. Cell and Tissue Research, 2018, 371, 567-576.	2.9	159
132	Repopulating the biliary tree from the peribiliary glands. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1524-1531.	3.8	30
133	Hemostasis and Thrombosis in Extreme Physiological and Pathological Conditions. Seminars in Thrombosis and Hemostasis, 2018, 44, 615-616.	2.7	4
134	Three strikes to a hemophilic joint bleed. Blood, 2018, 132, 1548-1550.	1.4	1
135	Elevated Plasma Levels of Cellâ€Free DNA During Liver Transplantation Are Associated With Activation of Coagulation. Liver Transplantation, 2018, 24, 1716-1725.	2.4	34
136	In vitro efficacy of proâ€and anticoagulant strategies in compensated and acutely ill patients with cirrhosis. Liver International, 2018, 38, 1988-1996.	3.9	35
137	Physiology, Prevention, and Treatment of Blood Loss During Liver Transplantation. , 2018, , 195-206.		0
138	Preemptively and non-preemptively transplanted patients show a comparable hypercoagulable state prior to kidney transplantation compared to living kidney donors. PLoS ONE, 2018, 13, e0200537.	2.5	10
139	Reversal of hypercoagulability in patients with <scp>HCV</scp>â€related cirrhosis after treatment with directâ€acting antivirals. Liver International, 2018, 38, 2210-2218.	3.9	39
140	Production of Physiologically Relevant Quantities of Hemostatic Proteins During Ex Situ Normothermic Machine Perfusion of Human Livers. Liver Transplantation, 2018, 24, 1298-1302.	2.4	15
141	Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease. Thrombosis Research, 2017, 150, 41-43.	1.7	5
142	In vitro uptake of recombinant factor <scp>VII</scp>a by megakaryocytes with subsequent production of platelets containing functionally active drug. British Journal of Haematology, 2017, 178, 482-486.	2.5	4
143	Hemostatic issues in pregnancy-induced liver disease. Thrombosis Research, 2017, 151, S78-S81.	1.7	8
144	Transient von Willebrand factorâ€mediated platelet influx stimulates liver regeneration after partial hepatectomy in mice. Liver International, 2017, 37, 1731-1737.	3.9	39

#	Article	IF	Citations
145	Fibrinolysis: Biochemistry, Clinical Aspects, and Therapeutic Potential. Seminars in Thrombosis and Hemostasis, 2017, 43, 113-114.	2.7	17
146	Oxygenated hypothermic machine perfusion after static cold storage improves endothelial function of extended criteria donor livers. Hpb, 2017, 19, 538-546.	0.3	39
147	Dual hypothermic oxygenated machine perfusion in liver transplants donated after circulatory death. British Journal of Surgery, 2017, 104, 907-917.	0.3	201
148	Management of Hemostatic Disorders in Patients With Advanced Liver Disease Admitted to an Intensive Care Unit. Transfusion Medicine Reviews, 2017, 31, 245-251.	2.0	14
149	Von Willebrand factor deficiency reduces liver fibrosis in mice. Toxicology and Applied Pharmacology, 2017, 328, 54-59.	2.8	16
150	Hemostatic and Non-hemostatic Functions of Platelets in Patients with Liver Disease. , 2017, , 1169-1181.		2
151	Value of Preoperative Hemostasis Testing in Patients with Liver Disease for Perioperative Hemostatic Management. Anesthesiology, 2017, 126, 338-344.	2.5	45
152	Global assays of fibrinolysis. International Journal of Laboratory Hematology, 2017, 39, e140-e141.	1.3	1
153	Activation of Fibrinolysis, But Not Coagulation, During End-Ischemic Ex Situ Normothermic Machine Perfusion of Human Donor Livers. Transplantation, 2017, 101, e42-e48.	1.0	27
154	Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 150-161.	2.3	92
155	Response to cautious use of platelet as relevant inducer of liver regeneration following partial hepatectomy in patients with metastatic hepatic carcinoma. Liver International, 2017, 37, 1918-1919.	3.9	0
156	Hemostatic Complications in Hepatobiliary Surgery. Seminars in Thrombosis and Hemostasis, 2017, 43, 732-741.	2.7	9
157	The cirrhotic platelet: Shedding light on an enigma. Hepatology, 2017, 65, 407-410.	7.3	17
158	Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis. Seminars in Thrombosis and Hemostasis, 2017, 43, 178-184.	2.7	48
159	Assessing in vivo platelet activation in patients with liver diseases. Journal of Thrombosis and Thrombolysis, 2017, 43, 52-53.	2.1	2
160	Re: Bleeding Risk and Management in Interventional Procedures in Chronic Liver Disease. Journal of Vascular and Interventional Radiology, 2017, 28, 1336-1337.	0.5	2
161	Response to the role of platelets on regenerating liver: Thoughts beyond parenchymal proliferation. Liver International, 2017, 37, 1917-1917.	3.9	0
162	Thromboelastography does not predict outcome in different etiologies of cirrhosis. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 275-285.	2.3	31

#	Article	IF	Citations
163	Cirrhosis as a risk factor for venous thrombosis. Thrombosis and Haemostasis, 2017, 117, 03-05.	3.4	24
164	Reply to: â€œProcoagulant imbalance in patients with non-alcoholic fatty liver diseaseâ€. Journal of Hepatology, 2017, 66, 250-251.	3.7	13
165	Normothermic machine perfusion reduces bile duct injury and improves biliary epithelial function in rat donor livers. Liver Transplantation, 2016, 22, 994-1005.	2.4	58
166	Role of hemostatic factors in hepatic injury and disease: animal models deâ€liver. Journal of Thrombosis and Haemostasis, 2016, 14, 1337-1349.	3.8	38
167	Alterations in Fibrin Structure in Patients with Liver Diseases. Seminars in Thrombosis and Hemostasis, 2016, 42, 389-396.	2.7	59
168	Fibrin fixes fibrosis. Blood, 2016, 127, 2662-2664.	1.4	1
169	Mechanisms of platelet-mediated liver regeneration. Blood, 2016, 128, 625-629.	1.4	56
170	Balance between von Willebrand factor and ADAMTS13 following major partial hepatectomy. British Journal of Surgery, 2016, 103, 735-743.	0.3	21
171	Preserved hemostatic status in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 65, 980-987.	3.7	72
172	Oxygenated Hypothermic Machine Perfusion After Static Cold Storage Improves Hepatobiliary Function of Extended Criteria Donor Livers. Transplantation, 2016, 100, 825-835.	1.0	94
173	Normothermic machine perfusion of donor livers using a novel hemoglobin based oxygen carrier solution, eliminating the need for human blood products. Hpb, 2016, 18, e73.	0.3	1
174	The Role of Fibrinogen and Factor XIII in Hemostasis, and the Identification and Treatment of Associated Disorders. Seminars in Thrombosis and Hemostasis, 2016, 42, 331-332.	2.7	6
175	Prediction of bleeding in cirrhosis patients: Is the forecast any clearer?. Hepatology, 2016, 64, 989-990.	7.3	20
176	Plasma molecules predicting liver dysfunction following partial hepatectomy are not only derived from platelet Î±â€granules. Hepatology, 2016, 64, 991-992.	7.3	3
177	Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. Journal of Thrombosis and Haemostasis, 2016, 14, 1054-1066.	3.8	102
178	Thrombocytopenia Is Associated With Multi-organ System Failure in Patients With Acute Liver Failure. Clinical Gastroenterology and Hepatology, 2016, 14, 613-620.e4.	4.4	70
179	A sustained decrease in plasma fibrinolytic potential following partial liver resection or pancreas resection. Thrombosis Research, 2016, 140, 36-40.	1.7	9
180	Evidence against a role for platelet-derived molecules in liver regeneration after partial hepatectomy in humans. Journal of Clinical and Translational Research, 2016, 2, 97-106.	0.3	1

#	Article	IF	Citations
181	Diffuse reflectance spectroscopy accurately quantifies various degrees of liver steatosis in murine models of fatty liver disease. Journal of Translational Medicine, 2015, 13, 309.	4.4	14
182	Coagulation activation during air travel is not initiated via the extrinsic pathway. British Journal of Haematology, 2015, 169, 903-905.	2.5	4
183	Horizontal RNA transfer mediates platelet-induced hepatocyte proliferation. Blood, 2015, 126, 798-806.	1.4	72
184	Ex Situ Normothermic Machine Perfusion of Donor Livers. Journal of Visualized Experiments, 2015, , e52688.	0.3	17
185	Thrombolytic protocol minimizes ischemicâ€type biliary complications in liver transplantation from donation after circulatory death donors. Liver Transplantation, 2015, 21, 1231-1232.	2.4	9
186	Decreased plasma levels of activated factor VII in patients with deep vein thrombosis. Journal of Thrombosis and Haemostasis, 2015, 13, 1320-1324.	3.8	4
187	Endâ€ischemic machine perfusion reduces bile duct injury in donation after circulatory death rat donor livers independent of the machine perfusion temperature. Liver Transplantation, 2015, 21, 1300-1311.	2.4	56
188	Ex vivo addition of fibrinogen concentrate improves the fibrin network structure in plasma samples taken during liver transplantation. Journal of Thrombosis and Haemostasis, 2015, 13, 2192-2201.	3.8	22
189	Vitamin E Attenuates the Progression of Non-Alcoholic Fatty Liver Disease Caused by Partial Hepatectomy in Mice. PLoS ONE, 2015, 10, e0143121.	2.5	17
190	Letter by Hugenholtz and Lisman Regarding Article, â€œPlasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathyâ€• Circulation, 2015, 131, e18.	1.6	7
191	The role of cell surfaces and cellular receptors in the mode of action of recombinant factor VIIa. Blood Reviews, 2015, 29, 223-229.	5.7	11
192	The role of platelets in liver regeneration â€“ What donâ€™t we know?. Journal of Hepatology, 2015, 63, 1537-1538.	3.7	12
193	Evidence against a role of serotonin in liver regeneration in humans. Hepatology, 2015, 62, 983-983.	7.3	13
194	Management of coagulation abnormalities in liver disease. Expert Review of Gastroenterology and Hepatology, 2015, 9, 103-114.	3.0	16
195	Infusion of <scp>DDAVP</scp> does not improve primary hemostasis in patients with cirrhosis. Liver International, 2015, 35, 1809-1815.	3.9	32
196	No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma. Thrombosis Research, 2015, 135, 292-297.	1.7	23
197	Hypercoagulability following major partial liver resection â€•detected by thrombomodulinâ€•modified thrombin generation testing. Alimentary Pharmacology and Therapeutics, 2015, 41, 189-198.	3.7	32
198	Development of a Hyperactive Primary Hemostatic System During Off-Pump Lung Transplantation Resulting From an Unbalance Between von Willebrand Factor and Its Cleaving Protease ADAMTS13. American Journal of Transplantation, 2015, 15, 1958-1966.	4.7	3

#	Article	IF	Citations
199	Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis. Hepatology, 2015, 61, 1435-1436.	7.3	49
200	Issues With Monitoring of Unfractionated Heparin in Cirrhosis. Therapeutic Drug Monitoring, 2015, 37, 279-280.	2.0	6
201	Preserved clot formation detected by the Thrombodynamics analyzer in patients with cirrhosis. Thrombosis Research, 2015, 135, 1012-1016.	1.7	14
202	Hemostatic Dysfunction in Liver Diseases. Seminars in Thrombosis and Hemostasis, 2015, 41, 445-446.	2.7	19
203	Rebalanced Hemostasis in Patients with Acute Liver Failure. Seminars in Thrombosis and Hemostasis, 2015, 41, 468-473.	2.7	86
204	Coagulationâ€driven platelet activation reduces cholestatic liver injury and fibrosis in mice. Journal of Thrombosis and Haemostasis, 2015, 13, 57-71.	3.8	45
205	Platelets and fibrin in progression of liver disease: friends or foes?. Journal of Thrombosis and Haemostasis, 2015, 13, 54-56.	3.8	18
206	Development of a Hypercoagulable Status in Patients Undergoing Off-Pump Lung Transplantation despite Prolonged Conventional Coagulation Tests. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 230-233.	5.6	10
207	Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?. Blood Reviews, 2015, 29, 127-136.	5.7	36
208	Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma. Platelets, 2015, 26, 577-582.	2.3	14
209	Liver Transplantation in Groningen, The Netherlands: A Single Center Status Report. Clinical Transplants, 2015, 31, 101-111.	0.2	0
210	Differential In Vitro Inhibition of Thrombin Generation by Anticoagulant Drugs in Plasma from Patients with Cirrhosis. PLoS ONE, 2014, 9, e88390.	2.5	79
211	Hypothermic Oxygenated Machine Perfusion Prevents Arteriolonecrosis of the Peribiliary Plexus in Pig Livers Donated after Circulatory Death. PLoS ONE, 2014, 9, e88521.	2.5	103
212	Injury to Peribiliary Glands and Vascular Plexus Before Liver Transplantation Predicts Formation of Non-Anastomotic Biliary Strictures.. Transplantation, 2014, 98, 175.	1.0	1
213	Injury of Peribiliary Glands and Vascular Plexus Before Liver Transplantation Predicts Formation of Non-Anastomotic Biliary Strictures.. Transplantation, 2014, 98, 342.	1.0	0
214	No increased systemic fibrinolysis in women with heavy menstrual bleeding. Journal of Thrombosis and Haemostasis, 2014, 12, 1488-1493.	3.8	12
215	Injury to peribiliary glands and vascular plexus before liver transplantation predicts formation of non-anastomotic biliary strictures. Journal of Hepatology, 2014, 60, 1172-1179.	3.7	170
216	Duct-to-duct reconstruction in liver transplantation for primary sclerosing cholangitis is associated with fewer biliary complications in comparison with hepaticojejunostomy. Liver Transplantation, 2014, 20, 457-463.	2.4	41

#	Article	IF	Citations
217	Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver International, 2014, 34, 26-32.	3.9	89
218	Hemostasis in Liver Disease: Implications of New Concepts for Perioperative Management. Transfusion Medicine Reviews, 2014, 28, 107-113.	2.0	108
219	Thrombomodulin-modified thrombin generation testing detects a hypercoagulable state in patients with cirrhosis regardless of the exact experimental conditions. Thrombosis Research, 2014, 134, 753-756.	1.7	39
220	Low molecular weight heparin in management and prevention of portal vein thrombosis. Thrombosis Research, 2014, 134, 761-762.	1.7	5
221	Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans. Thrombosis and Haemostasis, 2014, 112, 304-310.	3.4	6
222	Infusion of DDAVP Does Not Improve Primary Hemostasis in Patients with Cirrhosis. Blood, 2014, 124, 5044-5044.	1.4	1
223	Early elevated serum gamma glutamyl transpeptidase after liver transplantation is associated with better survival. F1000Research, 2014, 3, 85.	1.6	10
224	Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation. F1000Research, 2014, 3, 103.	1.6	6
225	Criteria for Viability Assessment of Discarded Human Donor Livers during Ex Vivo Normothermic Machine Perfusion. PLoS ONE, 2014, 9, e110642.	2.5	156
226	Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial. BMC Surgery, 2013, 13, 22.	1.3	65
227	Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient. Liver International, 2013, 33, 820-827.	3.9	68
228	Established and new-generation antithrombotic drugs in patients with cirrhosis â€“ Possibilities and caveats. Journal of Hepatology, 2013, 59, 358-366.	3.7	107
229	Decreased tissue factor pathway inhibitor (<scp>TFPI</scp>)â€dependent anticoagulant capacity in patients with cirrhosis who have decreased protein <scp>S</scp> but normal <scp>TFPI</scp> plasma levels. British Journal of Haematology, 2013, 162, 819-826.	2.5	14
230	Ex vivo Normothermic Machine Perfusion and Viability Testing of Discarded Human Donor Livers. American Journal of Transplantation, 2013, 13, 1327-1335.	4.7	243
231	An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome. Hepatology, 2013, 58, 752-761.	7.3	153
232	Increased mortality in systemic inflammatory response syndrome patients with high levels of coagulation factor VIIa. Journal of Thrombosis and Haemostasis, 2013, 11, 2111-2117.	3.8	17
233	In vitro effects of proteases in human pancreatic juice on stability of liquid and carrier-bound fibrin sealants. British Journal of Surgery, 2013, 100, 1498-1504.	0.3	9
234	The impact of hepatic steatosis on liver regeneration after partial hepatectomy. Liver International, 2013, 33, 469-475.	3.9	42

#	Article	IF	Citations
235	Routine coagulation assays underestimate levels of antithrombinâ€dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. British Journal of Haematology, 2013, 163, 666-673.	2.5	69
236	TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation. Thrombosis and Haemostasis, 2013, 109, 948-955.	3.4	19
237	Understanding and Managing the Coagulopathy of Liver Disease. , 2013, , 688-697.		0
238	Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia. New England Journal of Medicine, 2012, 367, 2055-2056.	27.0	15
239	Prohemostatic Interventions in Liver Surgery. Seminars in Thrombosis and Hemostasis, 2012, 38, 244-249.	2.7	28
240	Role of Fibrin Sealants in Liver Surgery. Digestive Surgery, 2012, 29, 54-61.	1.2	50
241	Fibrinolytic Proteins in Human Bile Accelerate Lysis of Plasma Clots and Induce Breakdown of Fibrin Sealants. Annals of Surgery, 2012, 256, 306-312.	4.2	25
242	The circulating platelet count is not dictated by the liver, but may be determined in part by the bone marrow: analyses from human liver and stem cell transplantations. Journal of Thrombosis and Haemostasis, 2012, 10, 1624-1630.	3.8	5
243	Physiology, Prevention, and Treatment of Blood Loss During Liver Transplantation. , 2012, , 169-179.		1
244	Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. Journal of Thrombosis and Haemostasis, 2012, 10, 1312-1319.	3.8	101
245	Bivalirudin is inferior to heparin in preservation of intraoperative autologous blood. Thrombosis Research, 2012, 130, 163-165.	1.7	16
246	Regeneration of human extrahepatic biliary epithelium: the peribiliary glands as progenitor cell compartment. Liver International, 2012, 32, 554-559.	3.9	54
247	Pitfalls in assessing platelet activation status in patients with liver disease. Liver International, 2012, 32, 1027-1027.	3.9	10
248	Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. Journal of Hepatology, 2012, 56, 129-136.	3.7	241
249	Platelet function in patients with cirrhosis. Journal of Hepatology, 2012, 56, 993-994.	3.7	21
250	Platelet Function in Stored Heparinised Autologous Blood Is Not Superior to in Patient Platelet Function during Routine Cardiopulmonary Bypass. PLoS ONE, 2012, 7, e33686.	2.5	7
251	Early hepatic regeneration index and completeness of regeneration at 6 months after partial hepatectomy. British Journal of Surgery, 2012, 99, 1113-1119.	0.3	37
252	Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO caseâ€“control study. British Journal of Haematology, 2012, 156, 252-258.	2.5	18

#	Article	IF	Citations
253	Plasma levels of Midkine (neurite growth-promoting factor 2) are not associated with plasma fibrinolytic potential or risk of venous thrombosis. Journal of Thrombosis and Haemostasis, 2012, 10, 964-966.	3.8	0
254	Beneficial effects of gaseous hydrogen sulfide in hepatic ischemia/reperfusion injury. Transplant International, 2012, 25, 897-908.	1.6	29
255	Recombinant factor VIIa to treat severe bleeding in patients with liver disease: Pitfalls and possibilities. Journal of Hepatology, 2011, 55, 950-951.	3.7	3
256	Anemia as a potential contributor to bleeding in patients with liver disease â€“ Neglected but not forgotten. Journal of Hepatology, 2011, 54, 594-595.	3.7	11
257	Prothrombotic Gene Polymorphisms: Possible Contributors to Hepatic Artery Thrombosis After Orthotopic Liver Transplantation. Transplantation, 2011, 92, 587-593.	1.0	16
258	Protection of Bile Ducts in Liver Transplantation: Looking Beyond Ischemia. Transplantation, 2011, 92, 373-379.	1.0	100
259	The hemostatic status of pediatric recipients of adult liver grafts suggests that plasma levels of hemostatic proteins are not regulated by the liver. Blood, 2011, 117, 2070-2072.	1.4	22
260	Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarction. Blood, 2011, 117, 6694-6701.	1.4	19
261	Genome scan of clot lysis time and its association with thrombosis in a proteinÂCâ€deficient kindred. Journal of Thrombosis and Haemostasis, 2011, 9, 1383-1390.	3.8	4
262	Activation of hemostasis in brain dead organ donors: an observational study. Journal of Thrombosis and Haemostasis, 2011, 9, 1959-1965.	3.8	23
263	The combination of primary sclerosing cholangitis and CCR5â€”32 in recipients is strongly associated with the development of nonanastomotic biliary strictures after liver transplantation. Liver International, 2011, 31, 1102-1109.	3.9	23
264	Towards a rational use of low-molecular-weight heparin in patients with cirrhosis. Liver International, 2011, 31, 1063-1063.	3.9	33
265	Hepatic Artery Diseases. Molecular Pathology Library, 2011, , 701-708.	0.1	0
266	Platelets Play an Important Role in the Recovery of Liver Dysfunction After Hepatic Resection. Annals of Surgery, 2010, 252, 709.	4.2	0
267	Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood, 2010, 116, 529-536.	1.4	73
268	Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood, 2010, 116, 113-121.	1.4	309
269	Activation of Coagulation by Living Donor Kidney Transplants Early After Reperfusion. American Journal of Transplantation, 2010, 10, 434-434.	4.7	2
270	The International Normalized Ratio (INR) in the MELD Score: Problems and Solutions. American Journal of Transplantation, 2010, 10, 1349-1353.	4.7	75

#	Article	IF	Citations
271	Hypofibrinolysis as a risk factor for recurrent venous thrombosis; results of the LETS followâ€up study. Journal of Thrombosis and Haemostasis, 2010, 8, 605-607.	3.8	28
272	Reporting prothrombin time results as international normalized ratios for patients with chronic liver disease. Journal of Thrombosis and Haemostasis, 2010, 8, 1410-1412.	3.8	30
273	Intact thrombomodulinâ€mediated regulation of fibrinolysis during and after liver transplantation, despite a profoundly defective thrombomodulinâ€mediated regulation of coagulation. Journal of Thrombosis and Haemostasis, 2010, 8, 1646-1649.	3.8	12
274	Transmission of idiopathic thrombocytopenic purpura during orthotopic liver transplantation. Transplant International, 2010, 23, 236-238.	1.6	17
275	Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome. Thrombosis and Haemostasis, 2010, 103, 1181-1187.	3.4	40
276	Immediate Postoperative Low Platelet Count is Associated With Delayed Liver Function Recovery After Partial Liver Resection. Annals of Surgery, 2010, 251, 300-306.	4.2	106
277	Activation and Regulation of Hemostasis in Acute Liver Failure and Acute Pancreatitis. Seminars in Thrombosis and Hemostasis, 2010, 36, 437-443.	2.7	29
278	The Role of Platelets in Liver Inflammation and Regeneration. Seminars in Thrombosis and Hemostasis, 2010, 36, 170-174.	2.7	54
279	Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. Journal of Hepatology, 2010, 52, 355-361.	3.7	191
280	The interaction of recombinant factor VIIa with platelet glycoprotein Ib. Thrombosis Research, 2010, 125, S13-S15.	1.7	6
281	Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood, 2010, 116, 878-885.	1.4	536
282	Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. Thrombosis and Haemostasis, 2009, 101, 465-470.	3.4	30
283	Factor XI Binding to Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1409-1410.	2.4	3
284	Inflammation Mediated Down-Regulation of Hepatobiliary Transporters Contributes to Intrahepatic Cholestasis and Liver Damage in Murine Biliary Atresia. Pediatric Research, 2009, 66, 380-385.	2.3	13
285	The Impact of the Fibrinolytic System on the Risk of Venous and Arterial Thrombosis. Seminars in Thrombosis and Hemostasis, 2009, 35, 468-477.	2.7	65
286	Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica, 2009, 94, 811-818.	3.5	42
287	Development of a Severe von Willebrand Factor/ADAMTS13 Dysbalance During Orthotopic Liver Transplantation. American Journal of Transplantation, 2009, 9, 1189-1196.	4.7	78
288	No evidence for systemic platelet activation during or after orthotopic liver transplantation. Liver Transplantation, 2009, 15, 956-962.	2.4	12

#	Article	IF	Citations
289	Hypofibrinolysis is a risk factor for arterial thrombosis at young age. British Journal of Haematology, 2009, 145, 115-120.	2.5	74
290	Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. British Journal of Haematology, 2009, 145, 121-127.	2.5	62
291	Hepatic artery thrombosis after liver transplantation: more than just a surgical complication?. Transplant International, 2009, 22, 162-164.	1.6	30
292	Staphylococcal superantigenâ€like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibα and αIIbβ3. Journal of Thrombosis and Haemostasis, 2009, 7, 1867-1874.	3.8	53
293	How to minimize blood loss during liver surgery in patients with cirrhosis. Hpb, 2009, 11, 453-458.	0.3	38
294	Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy?. Hpb, 2009, 11, 459-464.	0.3	63
295	Bleeding in Liver Surgery: Prevention and Treatment. Clinics in Liver Disease, 2009, 13, 145-154.	2.1	92
296	The Platelet and Platelet Function Testing in Liver Disease. Clinics in Liver Disease, 2009, 13, 11-20.	2.1	55
297	Effects of acidosis, alkalosis, hyperthermia and hypothermia on haemostasis: results of point of care testing with the thromboelastography analyser. Blood Coagulation and Fibrinolysis, 2009, 20, 436-439.	1.0	45
298	Platelet Transfusion During Liver Transplantation Is Associated with Increased Postoperative Mortality Due to Acute Lung Injury. Anesthesia and Analgesia, 2009, 108, 1083-1091.	2.2	198
299	Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. Thrombosis and Haemostasis, 2009, 101, 465-70.	3.4	6
300	Hemostasis in patients with liver disease. Acta Gastro-Enterologica Belgica, 2009, 72, 433-40.	1.0	3
301	Platelets in liver transplantation: Friend or foe?. Liver Transplantation, 2008, 14, 923-931.	2.4	92
302	Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leukemia Research, 2008, 32, 1078-1084.	0.8	65
303	Interlaboratory variability in assessment of the model of endâ€stage liver disease score. Liver International, 2008, 28, 1344-1351.	3.9	71
304	A heparin-bonded vascular graft generates no systemic effect on markers of hemostasis activation or detectable heparin-induced thrombocytopeniaâ€“associated antibodies in humans. Journal of Vascular Surgery, 2008, 47, 324-329.	1.1	33
305	The influence of the pulsatility of the blood flow on the extent of platelet adhesion. Thrombosis Research, 2008, 121, 821-825.	1.7	17
306	Salvianolic Acid B inhibits platelet adhesion under conditions of flow by a mechanism involving the collagen receptor α2β1. Thrombosis Research, 2008, 123, 298-305.	1.7	44

#	Article	IF	Citations
307	Tissue Factorâ€“Independent Effects of Recombinant Factor VIIa on Hemostasis. Seminars in Hematology, 2008, 45, S12-S15.	3.4	12
308	Cellâ€“collagen interactions: the use of peptide Toolkits to investigate collagenâ€“receptor interactions. Biochemical Society Transactions, 2008, 36, 241-250.	3.4	170
309	Mechanisms of the Factor V Leiden Paradox. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1872-1877.	2.4	47
310	The glycoprotein Ib-IX-V complex contributes to tissue factorâ€“independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood, 2008, 112, 3227-3233.	1.4	69
311	The two tales of coagulation in liver transplantation. Current Opinion in Organ Transplantation, 2008, 13, 298-303.	1.6	69
312	Synergistic Effects of Hypofibrinolysis and Genetic and Acquired Risk Factors on the Risk of a First Venous Thrombosis. PLoS Medicine, 2008, 5, e97.	8.4	96
313	Staphylococcal Superantigen-Like 5 Activates Platelets, and Supports Platelet Adhesion Under Flow Conditions, Which Is Mediated by GPIb- Alpha and Alpha-IIb-Beta-3. Blood, 2008, 112, 3922-3922.	1.4	0
314	Platelet Activation by Oxidized Low Density Lipoprotein Is Mediated by Cd36 and Scavenger Receptor-A. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2476-2483.	2.4	87
315	Hemostatic Alterations in Liver Disease: A Review on Pathophysiology, Clinical Consequences, and Treatment. Digestive Surgery, 2007, 24, 250-258.	1.2	155
316	Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood, 2007, 109, 2430-2437.	1.4	61
317	Fibrinolysis and the risk of venous and arterial thrombosis. Current Opinion in Hematology, 2007, 14, 242-248.	2.5	35
318	Antiplatelet medication after liver transplantation: Does it affect outcome?. Liver Transplantation, 2007, 13, 644-646.	2.4	17
319	Platelet adhesion to dimeric Î²2-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein IbÎ±and apolipoprotein E receptor 2â€². Journal of Thrombosis and Haemostasis, 2007, 5, 369-377.	3.8	106
320	A mechanism to safeguard platelet adhesion under high-shear flow: von Willebrand factor-glycoprotein Ib and integrin Î±2Î²1-collagen interactions make complementary, collagen-type-specific contributions to adhesion: a rebuttal. Journal of Thrombosis and Haemostasis, 2007, 5, 1338-1339.	3.8	1
321	GLYCOPROTEIN IB-ALPHA CONTRIBUTES TO TISSUE FACTOR-INDEPENDENT THROMBIN GENERATION BY RECOMBINANT FACTOR VIIA ON THE ACTIVATED PLATELET SURFACE. Journal of Thrombosis and Haemostasis, 2007, 5, O-S-042-O-S-042.	3.8	2
322	Heparin immobilization reduces thrombogenicity of small-caliber expanded polytetrafluoroethylene grafts. Journal of Vascular Surgery, 2006, 43, 587-591.	1.1	73
323	Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients. Thrombosis and Haemostasis, 2006, 96, 100-101.	3.4	49
324	A single high-affinity binding site for von Willebrand factor in collagen III, identified using synthetic triple-helical peptides. Blood, 2006, 108, 3753-3756.	1.4	112

#	Article	IF	Citations
325	Hemostasis in chronic liver disease. Journal of Thrombosis and Haemostasis, 2006, 4, 2059-2060.	3.8	27
326	Hemostasis in chronic liver disease. Journal of Thrombosis and Haemostasis, 2006, 4, 2061-2062.	3.8	16
327	Hemostasis in chronic liver disease. Journal of Thrombosis and Haemostasis, 2006, 4, 2062-2063.	3.8	14
328	No evidence for an intrinsic platelet defect in patients with liver cirrhosis â€“ studies under flow conditions. Journal of Thrombosis and Haemostasis, 2006, 4, 2070-2072.	3.8	60
329	The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. British Journal of Haematology, 2006, 134, 92-94.	2.5	49
330	Severe Prolongation of the INR in Spur Cell Anemia of Cirrhosis: True-True and Related?. Digestive Diseases and Sciences, 2006, 51, 1203-1205.	2.3	8
331	Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology, 2006, 44, 53-61.	7.3	534
332	Glycoprotein IbÎ±â€“Mediated Platelet Adhesion and Aggregation to Immobilized Thrombin Under Conditions of Flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 670-675.	2.4	27
333	Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. Journal of Experimental Medicine, 2006, 203, 1419-1425.	8.5	278
334	ID: 199 Binding of TAFI to collagen: a role for TAFI in the regulation of platelet adhesion?. Journal of Thrombosis and Haemostasis, 2006, 4, 208-208.	3.8	1
335	O-Linked Glycosylation with Sialylated T-Antigen: A Novel Carbohydrate Determinant of von Willebrand Factor Antigen Levels.. Blood, 2006, 108, 178-178.	1.4	4
336	Hypofibrinolysis as a Risk Factor for Venous Thrombosis.. Blood, 2006, 108, 272-272.	1.4	2
337	Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood, 2005, 105, 1102-1105.	1.4	246
338	Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. Journal of Thrombosis and Haemostasis, 2005, 3, 742-751.	3.8	83
339	Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. Journal of Thrombosis and Haemostasis, 2005, 3, 1993-1997.	3.8	183
340	Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thrombosis and Haemostasis, 2005, 94, 1341-1343.	3.4	37
341	Platelet aggregation: involvement of thrombin and fibrin(ogen). Frontiers in Bioscience - Landmark, 2005, 10, 2504.	3.0	51
342	Identification of the von Willebrand Factor Binding Site in Collagen Using Triple Helical Peptides.. Blood, 2005, 106, 413-413.	1.4	0

#	Article	IF	Citations
343	Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy. Biomedical and Environmental Sciences, 2005, 18, 260-4.	0.2	24
344	Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thrombosis and Haemostasis, 2005, 94, 1341-3.	3.4	8
345	Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism. Translational Research, 2004, 144, 100-107.	2.3	13
346	Circulating endothelial cells in cancer patients do not express tissue factor. Cancer Letters, 2004, 213, 241-248.	7.2	23
347	Recombinant factor VIIa restores aggregation of Î±IIbÎ²3-deficient platelets via tissue factorâ€“independent fibrin generation. Blood, 2004, 103, 1720-1727.	1.4	76
348	Recombinant Factor VIIa Enhances Platelet Adhesion and Aggregation under Flow Conditions at Normal and Reduced Platelet Count.. Blood, 2004, 104, 2618-2618.	1.4	0
349	Mechanism of Action of Recombinant Activated Factor VII. Transfusion Alternatives in Transfusion Medicine, 2003, 5, 5-10.	0.2	2
350	Rebuttal to: Effect of heparin on TAFI-dependent inhibition of fibrinolysis. Journal of Thrombosis and Haemostasis, 2003, 1, 200-201.	3.8	10
351	Mechanism of action of recombinant factor VIIa. Journal of Thrombosis and Haemostasis, 2003, 1, 1138-1139.	3.8	98
352	Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A. Journal of Thrombosis and Haemostasis, 2003, 1, 2175-2178.	3.8	26
353	Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. Journal of Thrombosis and Haemostasis, 2003, 1, 2368-2373.	3.8	70
354	Recombinant factor VIIa in orthotopic liver transplantation. Blood Coagulation and Fibrinolysis, 2003, 14, 169-174.	1.0	37
355	Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. Blood Coagulation and Fibrinolysis, 2003, 14, 557-562.	1.0	28
356	Recombinant factor VIIa enhances deposition of platelets with congenital or acquired Î±IIbÎ²3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factorâ€“independent thrombin generation. Blood, 2003, 101, 1864-1870.	1.4	107
357	Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. Blood Coagulation and Fibrinolysis, 2003, 14, 169-74.	1.0	12
358	Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood, 2002, 99, 175-179.	1.4	159
359	Haemostatic abnormalities in patients with liver disease. Journal of Hepatology, 2002, 37, 280-287.	3.7	212
360	Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology, 2002, 35, 616-621.	7.3	68

#	Article	IF	Citations
361	Thrombin-Activatable Fibrinolysis Inhibitor Deficiency in Cirrhosis Is Not Associated With Increased Plasma Fibrinolysis. Gastroenterology, 2001, 121, 131-139.	1.3	264
362	The Defective Down Regulation of Fibrinolysis in Haemophilia A Can Be Restored by Increasing the TAFI Plasma Concentration. Thrombosis and Haemostasis, 2001, 86, 1035-1039.	3.4	125
363	The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thrombosis and Haemostasis, 2001, 86, 1035-9.	3.4	25
364	Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thrombosis and Haemostasis, 1999, 81, 87-95.	3.4	11
365	Anticoagulation in thrombocytopenic patients â€“ time to rethink?. Journal of Thrombosis and Haemostasis, 0, , .	3.8	2